A Multicenter Randomized, Double-Blind, Placebo-controlled, Dosing, Safety and Efficacy Study of IMM 124-E (Hyperimmune Bovine Colostrum) for Patients With Severe Alcoholic Hepatitis

Trial Profile

A Multicenter Randomized, Double-Blind, Placebo-controlled, Dosing, Safety and Efficacy Study of IMM 124-E (Hyperimmune Bovine Colostrum) for Patients With Severe Alcoholic Hepatitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs IMM 124E (Primary)
  • Indications Alcoholic hepatitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TREAT
  • Most Recent Events

    • 19 Sep 2017 According to an Immuron media release, thus far, over 50% of the targeted 66 patients have been randomized into the study, whose top-line results are expected in Q1 2019.
    • 11 Aug 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
    • 11 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top